Diego L. Kaen

La Rioja, F, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 17, 2025

Real-World Outcomes in Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001).

Real-World Outcomes in Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001).

Journal: JCO global oncology

Published: October 03, 2025

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 09, 2025

Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.

Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.

Journal: International journal of environmental research and public health

Published: June 06, 2025

Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.

Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.

Journal: Oncotarget

Published: May 20, 2025

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 26, 2024

Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).

Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).

Journal: Clinical lung cancer

Published: June 29, 2024

Argentine consensus recommendations for lung cancer screening programmes: a RAND/UCLA-modified Delphi study.

Argentine consensus recommendations for lung cancer screening programmes: a RAND/UCLA-modified Delphi study.

Journal: BMJ open

Published: February 03, 2023

Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?

Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?

Journal: Advances in experimental medicine and biology

Published: January 01, 2022

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 13, 2021

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 27, 2021

Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group.

Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group.

Journal: Critical reviews in oncology/hematology

Published: May 28, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026